Log in

NASDAQ:FLDMFluidigm Competitors & Alternatives

$7.61
+0.83 (+12.24 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.99
Now: $7.61
$7.80
50-Day Range
$3.53
MA: $5.27
$7.42
52-Week Range
$1.17
Now: $7.61
$9.26
Volume3.79 million shs
Average Volume5.18 million shs
Market Capitalization$538.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35

Competitors

Fluidigm (NASDAQ:FLDM) Vs. TMO, ILMN, A, MTD, BIO, and PKI

Should you be buying FLDM stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Fluidigm, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), and PerkinElmer (PKI).

Thermo Fisher Scientific (NYSE:TMO) and Fluidigm (NASDAQ:FLDM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Earnings & Valuation

This table compares Thermo Fisher Scientific and Fluidigm's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion6.42$3.70 billion$12.3533.55
Fluidigm$117.24 million4.59$-64,790,000.00($0.53)-14.36

Thermo Fisher Scientific has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.5% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 89.8% of Fluidigm shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 2.2% of Fluidigm shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Thermo Fisher Scientific and Fluidigm, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific021202.86
Fluidigm01302.75

Thermo Fisher Scientific currently has a consensus price target of $420.50, suggesting a potential upside of 1.49%. Fluidigm has a consensus price target of $10.3333, suggesting a potential upside of 35.79%. Given Fluidigm's higher possible upside, analysts plainly believe Fluidigm is more favorable than Thermo Fisher Scientific.

Volatility and Risk

Thermo Fisher Scientific has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Fluidigm has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500.

Profitability

This table compares Thermo Fisher Scientific and Fluidigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific14.12%18.18%9.07%
Fluidigm-48.46%-23.13%-12.84%

Summary

Thermo Fisher Scientific beats Fluidigm on 10 of the 14 factors compared between the two stocks.

Illumina (NASDAQ:ILMN) and Fluidigm (NASDAQ:FLDM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Valuation & Earnings

This table compares Illumina and Fluidigm's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$3.54 billion14.76$1.00 billion$6.5754.13
Fluidigm$117.24 million4.59$-64,790,000.00($0.53)-14.36

Illumina has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Illumina and Fluidigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Illumina20.67%19.14%12.09%
Fluidigm-48.46%-23.13%-12.84%

Risk & Volatility

Illumina has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Fluidigm has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500.

Institutional and Insider Ownership

89.9% of Illumina shares are held by institutional investors. Comparatively, 89.8% of Fluidigm shares are held by institutional investors. 0.4% of Illumina shares are held by company insiders. Comparatively, 2.2% of Fluidigm shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Illumina and Fluidigm, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Illumina241002.50
Fluidigm01302.75

Illumina currently has a consensus price target of $341.3125, indicating a potential downside of 4.03%. Fluidigm has a consensus price target of $10.3333, indicating a potential upside of 35.79%. Given Fluidigm's stronger consensus rating and higher possible upside, analysts plainly believe Fluidigm is more favorable than Illumina.

Summary

Illumina beats Fluidigm on 10 of the 14 factors compared between the two stocks.

Fluidigm (NASDAQ:FLDM) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for Fluidigm and Agilent Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fluidigm01302.75
Agilent Technologies012802.40

Fluidigm currently has a consensus target price of $10.3333, indicating a potential upside of 35.79%. Agilent Technologies has a consensus target price of $82.8235, indicating a potential downside of 15.30%. Given Fluidigm's stronger consensus rating and higher possible upside, equities analysts clearly believe Fluidigm is more favorable than Agilent Technologies.

Volatility and Risk

Fluidigm has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Valuation & Earnings

This table compares Fluidigm and Agilent Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fluidigm$117.24 million4.59$-64,790,000.00($0.53)-14.36
Agilent Technologies$5.16 billion5.85$1.07 billion$3.1131.44

Agilent Technologies has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fluidigm and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fluidigm-48.46%-23.13%-12.84%
Agilent Technologies13.04%20.76%10.72%

Institutional & Insider Ownership

89.8% of Fluidigm shares are held by institutional investors. 2.2% of Fluidigm shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Agilent Technologies beats Fluidigm on 9 of the 14 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Fluidigm (NASDAQ:FLDM) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Mettler-Toledo International and Fluidigm, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International27001.78
Fluidigm01302.75

Mettler-Toledo International presently has a consensus price target of $720.7778, indicating a potential downside of 23.66%. Fluidigm has a consensus price target of $10.3333, indicating a potential upside of 35.79%. Given Fluidigm's stronger consensus rating and higher probable upside, analysts clearly believe Fluidigm is more favorable than Mettler-Toledo International.

Risk & Volatility

Mettler-Toledo International has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Fluidigm has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500.

Profitability

This table compares Mettler-Toledo International and Fluidigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International18.61%138.77%20.40%
Fluidigm-48.46%-23.13%-12.84%

Institutional & Insider Ownership

94.2% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 89.8% of Fluidigm shares are held by institutional investors. 3.2% of Mettler-Toledo International shares are held by insiders. Comparatively, 2.2% of Fluidigm shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mettler-Toledo International and Fluidigm's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion7.50$561.11 million$22.7741.47
Fluidigm$117.24 million4.59$-64,790,000.00($0.53)-14.36

Mettler-Toledo International has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Summary

Mettler-Toledo International beats Fluidigm on 10 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Fluidigm (NASDAQ:FLDM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Profitability

This table compares Bio-Rad Laboratories and Fluidigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories84.89%3.66%2.65%
Fluidigm-48.46%-23.13%-12.84%

Risk & Volatility

Bio-Rad Laboratories has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Fluidigm has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500.

Valuation and Earnings

This table compares Bio-Rad Laboratories and Fluidigm's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion6.73$1.76 billion$7.0674.24
Fluidigm$117.24 million4.59$-64,790,000.00($0.53)-14.36

Bio-Rad Laboratories has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Bio-Rad Laboratories and Fluidigm, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00313.25
Fluidigm01302.75

Bio-Rad Laboratories presently has a consensus price target of $511.25, suggesting a potential downside of 2.46%. Fluidigm has a consensus price target of $10.3333, suggesting a potential upside of 35.79%. Given Fluidigm's higher possible upside, analysts plainly believe Fluidigm is more favorable than Bio-Rad Laboratories.

Insider & Institutional Ownership

62.9% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 89.8% of Fluidigm shares are held by institutional investors. 27.5% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 2.2% of Fluidigm shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bio-Rad Laboratories beats Fluidigm on 11 of the 14 factors compared between the two stocks.

Fluidigm (NASDAQ:FLDM) and PerkinElmer (NYSE:PKI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares Fluidigm and PerkinElmer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fluidigm-48.46%-23.13%-12.84%
PerkinElmer9.87%18.41%7.95%

Analyst Recommendations

This is a summary of current ratings for Fluidigm and PerkinElmer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fluidigm01302.75
PerkinElmer08602.43

Fluidigm presently has a consensus target price of $10.3333, indicating a potential upside of 35.79%. PerkinElmer has a consensus target price of $94.4286, indicating a potential downside of 20.87%. Given Fluidigm's stronger consensus rating and higher possible upside, equities analysts plainly believe Fluidigm is more favorable than PerkinElmer.

Earnings and Valuation

This table compares Fluidigm and PerkinElmer's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fluidigm$117.24 million4.59$-64,790,000.00($0.53)-14.36
PerkinElmer$2.88 billion4.61$227.56 million$4.1029.10

PerkinElmer has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than PerkinElmer, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

89.8% of Fluidigm shares are held by institutional investors. Comparatively, 93.3% of PerkinElmer shares are held by institutional investors. 2.2% of Fluidigm shares are held by insiders. Comparatively, 0.6% of PerkinElmer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Fluidigm has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, PerkinElmer has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Summary

PerkinElmer beats Fluidigm on 10 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
1.9$414.33+0.3%$163.90 billion$25.54 billion44.84
Illumina logo
ILMN
Illumina
1.4$355.66+12.3%$52.28 billion$3.54 billion76.00Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
Heavy News Reporting
Agilent Technologies logo
A
Agilent Technologies
1.5$97.78+0.3%$30.19 billion$5.16 billion45.06Increase in Short Interest
Mettler-Toledo International logo
MTD
Mettler-Toledo International
0.9$944.17+0.6%$22.57 billion$3.01 billion42.36Insider Selling
Decrease in Short Interest
Analyst Revision
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$524.13+0.2%$15.56 billion$2.31 billion8.13Analyst Revision
PerkinElmer logo
PKI
PerkinElmer
1.7$119.33+0.2%$13.29 billion$2.88 billion45.37Decrease in Short Interest
Waters logo
WAT
Waters
1.2$212.34+0.8%$13.15 billion$2.41 billion26.44Decrease in Short Interest
Charles River Laboratories Intl. logo
CRL
Charles River Laboratories Intl.
1.3$221.60+1.7%$11.01 billion$2.62 billion40.81Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
BIO-TECHNE logo
TECH
BIO-TECHNE
1.5$265.76+0.3%$10.16 billion$738.69 million45.90Earnings Announcement
Analyst Upgrade
Bruker logo
BRKR
Bruker
2.2N/AN/A$6.81 billion$2.07 billion33.69Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
Luminex logo
LMNX
Luminex
1.1$32.06+3.3%$1.49 billion$334.64 million139.40Earnings Announcement
Analyst Upgrade
Insider Selling
Analyst Revision
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.5$4.73+13.7%$729.89 million$90.89 million-14.33Earnings Announcement
Analyst Revision
Heavy News Reporting
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.6$4.19+4.5%$160.81 million$116.18 million-19.05Earnings Announcement
High Trading Volume
aTyr Pharma logo
LIFE
aTyr Pharma
2.0$4.00+0.3%$37.41 million$420,000.00-0.88Upcoming Earnings
Heavy News Reporting
This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.